Last updated: August 25, 2026
Carboprost tromethamine is a mature injectable uterotonic used primarily for postpartum hemorrhage caused by uterine atony and for second-trimester pregnancy termination. Its commercial market is small in absolute volume but strategically important because hospitals require immediate availability, approved substitutes are limited, and supply interruptions can create sharp price increases. The product has no meaningful remaining branded exclusivity, and financial performance depends more on manufacturing reliability, hospital contracts, shortages, and regulatory compliance than on patent protection.
What is carboprost tromethamine used for?
Carboprost tromethamine is a synthetic analogue of prostaglandin F2 alpha. In the United States, the reference product is Hemabate, supplied as a 250 microgram/mL intramuscular injection.
The FDA-approved uses include:
- Severe postpartum hemorrhage caused by uterine atony that has not responded to conventional treatment
- Management of second-trimester abortion caused by intrauterine fetal death, failed expulsion after rupture of membranes, or failed expulsion following other methods
- Treatment of nonmetastatic gestational trophoblastic disease in selected circumstances [1]
The principal commercial use is obstetric hemorrhage management. Hospitals typically stock carboprost in obstetric operating rooms, labor and delivery units, emergency departments, and pharmacy emergency kits.
Carboprost is administered intramuscularly or directly into the myometrium. It is generally used after or alongside oxytocin, uterine massage, and other interventions. It is contraindicated or used cautiously in patients with asthma because prostaglandin-mediated bronchoconstriction can cause severe respiratory complications [1].
What is the FDA regulatory status of carboprost tromethamine?
The FDA reference product is Hemabate, associated with New Drug Application 018032. Carboprost tromethamine is an established prescription injectable drug rather than a new molecular entity.
| Regulatory attribute |
Status |
| Active ingredient |
Carboprost tromethamine |
| Drug class |
Prostaglandin F2 alpha analogue; uterotonic |
| Primary dosage form |
250 mcg/mL sterile injection |
| Primary route |
Intramuscular; intramyometrial use is described in labeling |
| Reference product |
Hemabate |
| Reference sponsor |
Pharmacia & Upjohn, now within Pfizer’s legacy product portfolio |
| FDA pathway for competitors |
Abbreviated New Drug Application |
| Controlled-substance status |
Not a controlled substance |
| Main hospital use |
Postpartum hemorrhage caused by uterine atony |
| Main safety limitation |
Bronchospasm risk, particularly in asthma |
FDA product availability has changed over time as branded and generic suppliers have entered or exited the market. The product has also appeared on FDA drug-shortage materials, reflecting the vulnerability of sterile injectable supply chains [2].
When does carboprost tromethamine lose exclusivity?
Carboprost tromethamine lost meaningful market exclusivity decades ago. The active ingredient and the core obstetric use are protected by old intellectual property that is no longer a practical barrier to generic entry.
No current patent estate is generally recognized as protecting the basic carboprost tromethamine injection against ANDA competition. The commercial rights associated with Hemabate therefore derive primarily from the approved product, manufacturing capability, customer relationships, and supply reliability rather than from enforceable patent exclusivity.
What is the Orange Book status of carboprost tromethamine?
The FDA Orange Book should be reviewed for the current listing of Hemabate and any approved generic products. For a mature injectable such as carboprost tromethamine, the key Orange Book questions are:
- Whether the reference product remains actively marketed
- Which patents, if any, are listed for the reference product
- Whether any listed patents have expired
- Whether generic applicants received paragraph IV certification
- Whether the product has an approved therapeutic-equivalence code
Because carboprost tromethamine is an old small-molecule injectable with generic availability, the Orange Book is unlikely to show commercially meaningful unexpired patent protection covering the basic product. A current product-specific Orange Book review is still necessary before relying on any conclusion for litigation, licensing, or acquisition purposes [3].
How many patents cover carboprost tromethamine?
The number of commercially relevant unexpired U.S. patents covering the standard 250 mcg/mL carboprost tromethamine injection is effectively zero based on the product’s age and generic status.
The historical patent landscape is more important than the current one. Early patents covered prostaglandin analogues, synthesis, therapeutic use, or pharmaceutical compositions. Those rights would have expired long before the current generic market developed.
Potential residual IP issues could arise from:
- Novel container-closure systems
- Stability-enhancing formulations
- Specialized prefilled syringes
- Cold-chain or packaging designs
- Combination obstetric treatment protocols
- Manufacturing-process claims
Such patents would not necessarily block a conventional generic vial or ampule. The main barrier is the FDA-approved manufacturing process and sterile injectable quality system, not molecule-level patent protection.
Which companies manufacture or market carboprost tromethamine?
The U.S. market has historically included Pfizer’s Hemabate and generic injectable suppliers. Generic sterile-injectable manufacturers and contract manufacturers may change over time as facilities are transferred, products are discontinued, or supply agreements are renegotiated.
Known market participants have included:
- Pfizer and legacy Pharmacia entities for Hemabate
- Hikma Pharmaceuticals and other generic injectable suppliers in selected markets
- Hospital-focused generic and specialty-injectable manufacturers
- Contract manufacturing organizations supporting approved ANDA holders
Supplier participation must be confirmed against current FDA listings and National Drug Code data because marketing status can change without a major public transaction. A manufacturer may retain an approved product while having limited commercial distribution.
What is the market size for carboprost tromethamine?
Public market-size estimates for carboprost tromethamine are not reliable enough to support a precise global revenue figure. The product is usually included in broader uterotonic, obstetric hemorrhage, or sterile injectable categories rather than disclosed as a standalone line item.
The market has four defining characteristics:
| Market factor |
Commercial effect |
| Low unit volume |
Limits total addressable revenue |
| Emergency clinical use |
Supports hospital stocking even when utilization is low |
| Few practical substitutes |
Increases procurement sensitivity |
| Sterile injectable manufacturing |
Raises entry and supply-chain barriers |
Carboprost is used infrequently relative to routine oxytocin but must remain immediately available. This creates a stockpiling market in which demand is driven by hospital census, delivery volume, maternal hemorrhage incidence, and formulary policy.
Demand is also affected by clinical guidelines. The American College of Obstetricians and Gynecologists identifies uterotonics, including carboprost, as part of the treatment framework for postpartum hemorrhage when uterine atony is present [4].
What drives the financial trajectory of carboprost tromethamine?
The financial trajectory is driven by price and supply rather than volume growth.
Hospital procurement and shortage premiums
A sterile injectable product can generate materially higher revenue during a shortage even if prescription volume remains stable. Hospitals and group purchasing organizations may accept higher prices to preserve emergency inventory, particularly when alternatives are contraindicated or unavailable.
Shortages can result from:
- Manufacturing-site interruptions
- Component shortages
- Quality investigations
- Batch failures
- Limited active pharmaceutical ingredient supply
- Discontinuation by one of a small number of suppliers
FDA shortage records have periodically identified carboprost injection availability constraints. ASHP shortage data also tracks hospital-facing supply problems and alternative-product recommendations [2, 5].
Low promotional spending
Carboprost requires little traditional physician promotion. Clinical adoption is established, and prescribing is protocol-driven. Commercial spending is concentrated in:
- Regulatory maintenance
- Pharmacovigilance
- Sterile manufacturing
- Hospital contracting
- Inventory management
- Shortage communication
This structure can support attractive gross margins for a reliable supplier despite a small overall market.
Limited volume expansion
The product is unlikely to achieve high unit-volume growth because it treats an acute event rather than a chronic disease. Revenue growth depends mainly on:
- Increased births in served markets
- Greater recognition and treatment of postpartum hemorrhage
- Expanded hospital stocking
- Higher contract prices
- Entry into markets with limited local supply
The World Health Organization estimates that postpartum hemorrhage remains a major cause of maternal mortality worldwide, particularly in low- and middle-income countries [6]. That clinical need supports long-term demand, but reimbursement and procurement constraints limit the commercial value of many international markets.
How does carboprost compare with competing postpartum hemorrhage drugs?
Carboprost competes within a protocol rather than as a stand-alone replacement for one product.
| Drug |
Main role |
Key limitation |
Commercial position |
| Oxytocin |
First-line uterotonic |
May be inadequate in severe atony |
High-volume, low-cost hospital standard |
| Misoprostol |
Alternative or adjunct uterotonic |
Variable tolerability and route-specific effects |
Broad access, especially where injectables are limited |
| Methylergonovine |
Uterotonic for selected patients |
Avoid in significant hypertension or preeclampsia |
Established low-cost injectable/oral option |
| Carboprost |
Rescue uterotonic for uterine atony |
Avoid or use cautiously in asthma |
Low-volume, high-criticality injectable |
| Tranexamic acid |
Antifibrinolytic, not a uterotonic |
Different mechanism and timing requirements |
Important adjunct in postpartum hemorrhage |
Carboprost has a narrower patient population than oxytocin because of the asthma warning. Methylergonovine is constrained by hypertension. Misoprostol has broader storage and administration advantages but can cause fever and gastrointestinal adverse effects. These clinical limitations reduce direct substitution and support continued hospital demand for carboprost [4, 6].
What formulation patents and manufacturing barriers protect the market?
The principal barrier is sterile injectable production. A prospective entrant must demonstrate:
- Validated aseptic processing
- Sterility assurance
- Container-closure integrity
- Consistent potency at the microgram dose
- Stability under refrigerated storage
- Compliance with current good manufacturing practices
- Reliable supply of drug substance and packaging components
Carboprost tromethamine is typically supplied in a refrigerated sterile solution. Temperature control and short-notice hospital distribution increase logistics costs. These factors can deter small manufacturers even though molecule-level patents have expired.
A formulation patent could be commercially relevant if it covered a materially improved stability profile, ready-to-use delivery device, or storage condition. A conventional generic vial would generally avoid such claims if its composition and packaging differ.
Are there paragraph IV challenges or generic litigation?
Carboprost tromethamine has not been associated with a major current paragraph IV litigation campaign comparable to newer high-revenue drugs. The product’s age and generic availability reduce the incentive for patent challengers and brand sponsors to pursue extended patent litigation.
Generic applicants could file paragraph IV certifications if a listed patent remained in force. The resulting litigation risk would depend on:
- The specific Orange Book-listed patent
- The filing date of the ANDA
- Whether the patent covers the product, method, or packaging
- The commercial significance of the challenged formulation
- Whether the brand sponsor had an enforceable basis for a 30-month stay
For the standard product, launch timing is more likely to depend on ANDA review, manufacturing readiness, and supplier capacity than on patent settlements.
Are there biosimilar risks for carboprost tromethamine?
There is no biosimilar risk. Carboprost tromethamine is a chemically synthesized small molecule, not a biologic. Competition proceeds through the generic drug pathway under section 505(j) of the Federal Food, Drug, and Cosmetic Act.
The relevant competitive risks are:
- Additional ANDA approvals
- Supplier discontinuations
- Contract repricing
- Import or manufacturing disruptions
- Hospital conversion to alternative uterotonics
- New delivery systems that reduce preparation time
What generic launch scenarios exist?
Three scenarios are commercially plausible.
Stable multi-supplier market
Two or more reliable suppliers maintain adequate inventory. Prices remain competitive, margins are moderate, and hospitals retain carboprost on formulary because of its rescue role.
Single-supplier or constrained market
One supplier exits or experiences a manufacturing problem. The remaining supplier gains pricing power, while hospitals ration inventory or use methylergonovine, misoprostol, or other protocol-based alternatives.
New entrant with differentiated delivery
A supplier introduces a ready-to-administer syringe, improved packaging, or broader distribution. The entrant may gain share despite the absence of patent protection if it reduces pharmacy preparation time and waste.
What is the geographic coverage of the carboprost market?
The United States is the most commercially structured market because hospitals use formal formularies, group purchasing contracts, and FDA-regulated injectable products. Europe, Canada, Latin America, and emerging markets use prostaglandin-based uterotonics, but product names, registration status, reimbursement, and procurement models differ.
International growth is limited by:
- National tender pricing
- Cold-chain requirements
- Uneven maternal-care infrastructure
- Local registration costs
- Availability of misoprostol and oxytocin
- Lower willingness to pay for emergency stock
The strongest commercial opportunity is generally in markets where obstetric hospitals require injectable rescue therapy and have limited supplier redundancy.
What litigation, licensing deals, and settlements affect carboprost?
No major current licensing transaction, patent settlement, or publicly disclosed litigation event appears to define the commercial outlook for standard carboprost tromethamine injection. The product is commercially mature, and market access is primarily operational.
Any future transaction would more likely involve:
- Acquisition of an injectable portfolio
- Transfer of an ANDA
- Contract manufacturing
- Regional distribution rights
- Supply agreements with hospitals or group purchasing organizations
A transaction involving carboprost should be valued on approved-market status, manufacturing capacity, shortage history, customer contracts, and regulatory compliance rather than on residual patent life.
How strong is the patent estate for carboprost tromethamine?
The patent estate is weak for the conventional product and strong only in the operational sense that sterile manufacturing is difficult to replicate.
| Asset category |
Current strength |
| Core molecule |
No meaningful remaining exclusivity |
| Standard injection composition |
Low patent protection |
| Basic postpartum hemorrhage use |
No meaningful exclusivity |
| Novel delivery system |
Potentially protectable |
| Manufacturing process |
Possible trade-secret and process-control value |
| Sterile facility qualification |
High practical entry barrier |
| Hospital supply contracts |
Potential commercial barrier |
| Regulatory history |
Valuable but nonexclusive |
The most defensible commercial position belongs to a supplier with dependable production and regulatory execution.
What revenue exposure exists for manufacturers?
Product-level revenue is generally not disclosed by public companies. Carboprost is usually grouped within broader sterile injectables, women’s health, or hospital products segments.
Revenue exposure should therefore be modeled using operational variables:
- Number of hospital accounts
- Annual birth volume in served institutions
- Units purchased per delivery
- Emergency-stock replacement rate
- Average net selling price
- Shortage-related price uplift
- Supplier share
- Manufacturing utilization
- Product write-offs from expiration
A supplier can have modest absolute revenue but disproportionate strategic value if carboprost supports a broader obstetric injectable portfolio or strengthens hospital contracting relationships.
Key Takeaways
- Carboprost tromethamine is a mature, low-volume, high-criticality sterile injectable.
- Hemabate has no meaningful remaining core patent exclusivity.
- The product is regulated as a conventional small-molecule prescription drug, not a biologic.
- There is no biosimilar pathway or biosimilar threat.
- Financial performance depends on manufacturing reliability, hospital contracts, shortages, and net pricing.
- Generic competition is established, but sterile injectable barriers limit the number of dependable suppliers.
- FDA and ASHP shortage records are more important to near-term market analysis than patent litigation.
- The principal competitors are oxytocin, methylergonovine, misoprostol, and tranexamic acid, although clinical substitution is constrained by differing mechanisms and contraindications.
- Product-level revenue is generally not publicly disclosed, making supplier-level operational modeling more reliable than headline market-size estimates.
- A new entrant would need to differentiate through supply reliability, delivery format, regulatory execution, or geographic distribution.
FAQs About Carboprost Tromethamine Commercial and Patent Risk
Is carboprost tromethamine still commercially available?
Yes. Availability varies by supplier, market, dosage form, and shortage conditions. Current FDA and manufacturer listings should be checked because sterile injectable products can move in and out of active distribution.
Is Hemabate protected by a patent?
The original product’s core patent protection expired long ago. Any current patent issue would likely involve a specific formulation, package, delivery system, or manufacturing process rather than the basic carboprost injection.
Can pharmacies substitute generic carboprost for Hemabate?
Substitution depends on the approved generic product, therapeutic-equivalence designation, state pharmacy law, hospital policy, and inventory. Hospitals typically manage the product through formulary and pharmacy-and-therapeutics procedures.
What is the biggest commercial risk for carboprost manufacturers?
The largest risk is sterile injectable supply disruption. A facility failure, quality investigation, or supplier exit can cause lost sales, regulatory scrutiny, and emergency procurement costs.
Could a prefilled carboprost syringe support premium pricing?
Yes, if the device is FDA-approved, stable under the required storage conditions, compatible with emergency workflows, and supported by reliable supply. The commercial premium would come from reduced preparation time and lower medication-error risk rather than from molecule-level exclusivity.
References
- U.S. Food and Drug Administration. (n.d.). Hemabate carboprost tromethamine injection prescribing information. https://www.accessdata.fda.gov
- U.S. Food and Drug Administration. (n.d.). Drug shortages: Carboprost tromethamine injection. https://www.accessdata.fda.gov/scripts/drugshortages/
- U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book
- American College of Obstetricians and Gynecologists. (2019). Practice Bulletin No. 183: Postpartum hemorrhage. Obstetrics & Gynecology, 130(4), e168-e186.
- American Society of Health-System Pharmacists. (n.d.). Drug shortages statistics and management resources. https://www.ashp.org/drug-shortages
- World Health Organization. (2023). Postpartum haemorrhage: A new definition and management guidance. https://www.who.int/publications/i/item/9789240088501
